Table 11. c.(487T>A) and clinical features in 45 patients with missense mutations.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clinical features | N | c.(487T>A) | X2 | P  |
| With Without |
| Age |  |  |  |  |  |
| ≤45>45 | 1629 | 15(93.75%)1(3.45%) | 1(6.25%)28(96.55%) |  | P<0.001 |
|  |  |  |  |  |  |
| Tumor size |  |  |  |  |  |
| ≤ 2cm | 23 | 10(43.48%) | 13(56.52%) |  |  |
| >2cm, ≤ 5cm>5cm | 184 | 6(33.33%)0(0.00%) | 12(66.67%)4(100.00%) | 2.498 | 0.346 |
|  |  |  |  |  |  |
| Clinical stage |  |  |  |  |  |
|  I, II | 9 | 2(22.22%) | 7(77.78%) |  |  |
| III，IV | 36 | 14(38.89%) | 22(61.11%) |  | 0.456 |
| Molecular subtype |  |  |  |  |  |
|   Luminal A | 15 | 4(26.67%) | 11(73.33%) |  |  |
| Luminal B | 12 | 6(50.00%) | 6(50.00%) |  |  |
| HER-2+ | 5 | 2(40.00%) | 3(60.00%) |  |  |
| TNBC | 13 | 4(30.77%) | 9(69.23%) | 1.891 | 0.608 |
| Lymph-node metastasis |  |  |  |  |  |
|  Yes | 27 | 13(48.15%) | 14(51.85%) |  |  |
| No | 18 | 3(16.67%) | 15(83.33%) |  | 0.055 |
|  |  |  |  |  |  |
| ER |  |  |  |  |  |
| +- | 2718 | 10(37.04%)6(33.33%) | 17(62.96%)12(66.67%) | 0.065 | 1.000 |
|  |  |  |  |  |  |
| PR+- | 1530 | 4(26.67%)12(40.00%) | 11(73.33%)18(60.00%) |  | 0.514 |
|  |  |  |  |  |  |
| HER2+ | 12 | 6(50.00%) | 6(50.00%) |  |  |
| - | 33 | 10(30.30%) | 23(69.70%) | 1.490 | 0.296 |
|  |  |  |  |  |  |
| Ki-67 |  |  |  |  |  |
| ≤30% | 23 | 7(30.43%) | 16(69.57%) |  |  |
| >30% | 22 | 9(40.91%) | 13(59.09%) | 0.538 | 0.542 |

P-value <0.05, statistically significant.